Canandaigua National Trust Co of Florida Makes New $1.03 Million Investment in Abbott Laboratories $ABT

Key Points

• Canandaigua National Trust Co. of Florida acquired 10,454 Abbott Laboratories shares worth approximately $1.03 million in the third quarter. Institutional investors and hedge funds collectively own 75.18% of Abbott’s stock.
• Analysts remain broadly bullish, with a consensus rating of “Moderate Buy” and an average price target of $118.88. Recent targets range from $112 to $130, including upgrades from Piper Sandler, JPMorgan and Wolfe Research.
• Abbott reported quarterly revenue of $12.59 billion, up 13% year over year, and earnings of $1.31 per share, exceeding expectations. The company declared a quarterly dividend of $0.63 per share, equivalent to a 2.6% annual yield.

Canandaigua National Trust Co of Florida purchased a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 10,454 shares of the healthcare product maker's stock, valued at approximately $1,033,000.

Several other large investors also recently bought and sold shares of the stock. Juncture Wealth Strategies LLC acquired a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $658,000. Aureus Asset Management LLC raised its position in Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock valued at $34,078,000 after purchasing an additional 66,422 shares during the last quarter. Thompson Investment Management Inc. boosted its stake in Abbott Laboratories by 786.0% during the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker's stock worth $1,276,000 after purchasing an additional 12,474 shares during the period. Parnassus Investments LLC grew its position in Abbott Laboratories by 17.5% during the 4th quarter. Parnassus Investments LLC now owns 616,351 shares of the healthcare product maker's stock worth $77,223,000 after purchasing an additional 91,897 shares during the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new position in Abbott Laboratories in the second quarter valued at $4,889,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Piper Sandler reiterated an "overweight" rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. JPMorgan Chase & Co. upped their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Wells Fargo & Company lifted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Finally, UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $118.88.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays initiated coverage with an “overweight” rating and a $120 price target, implying substantial upside from recent levels. The firm’s bullish view reflects growing confidence in Abbott’s medical-device and broader medtech exposure. Stryker, Abbott among overweight ideas as Barclays turns bullish on MedTech
• Positive Sentiment: Analyst research highlighted a bullish initiation on Abbott, adding to favorable sentiment around the shares. This Abbott Analyst Begins Coverage On A Bullish Note
• Positive Sentiment: Evercore ISI raised its price target to $124 from $120 while maintaining an “outperform” rating, signaling confidence in Abbott’s longer-term earnings potential. Evercore ISI Adjusts Price Target on Abbott Laboratories
• Positive Sentiment: Abbott introduced Ensure Max Protein 3-in-1 Muscle Support, combining protein, creatine, and HMB in one product. The launch expands its consumer-health offering and targets growing mainstream wellness demand, though the near-term financial effect is likely limited. Abbott introduces Ensure Max Protein 3-in-1 Muscle Support
• Neutral Sentiment: Commentary describes ABT as a potential dividend bargain following its 2026 decline. Abbott has made 411 consecutive quarterly dividend payments since 1924, appealing to income-focused investors, but the company is not currently showing rapid growth trends. Is Abbott Laboratories a Dividend Bargain After Its 2026 Selloff?
• Negative Sentiment: Abbott recently declined even as the broader market advanced, indicating continued stock-specific pressure and cautious investor sentiment. The pullback may improve dividend valuation, but it also reflects concerns about growth and near-term momentum. Abbott Stock Drops Despite Market Gains

Abbott Laboratories Stock Performance

NYSE:ABT traded up $0.54 during mid-day trading on Wednesday, reaching $98.70. The stock had a trading volume of 9,392,108 shares, compared to its average volume of 11,346,689. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a market capitalization of $170.79 billion, a price-to-earnings ratio of 31.94, a PEG ratio of 1.86 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $135.13. The business has a 50 day simple moving average of $106.71 and a 200 day simple moving average of $98.45.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the business posted $1.26 EPS. The company's revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. Abbott Laboratories's dividend payout ratio is 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories NYSE: ABT is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott's medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.